Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.700
-0.040 (-0.84%)
At close: Jul 31, 2026, 4:00 PM EDT
4.705
+0.005 (0.11%)
After-hours: Jul 31, 2026, 7:34 PM EDT
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
376.13M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Sutro Biopharma | 99.61M |
| Autolus Therapeutics | 92.62M |
| Enanta Pharmaceuticals | 69.21M |
| Editas Medicine | 38.69M |
| vTv Therapeutics | 36.84M |
| Scribe Therapeutics | 36.28M |
| C4 Therapeutics | 34.86M |
AVIR News
- 3 days ago - Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints - TheFly
- 3 days ago - Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus - GlobeNewsWire
- 17 days ago - Atea Pharmaceuticals initiates AT-587 clinical trial - TheFly
- 17 days ago - Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewsWire
- 5 weeks ago - Atea Pharmaceuticals completes patient enrollment in C-FORWARD trial - TheFly
- 5 weeks ago - Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 2 months ago - Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 - GlobeNewsWire